The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Addressing phenoconversion: the Achilles' heel of personalized medicine
Open accessAbstract
Phenoconversion is a phenomenon that converts genotypic extensive metabolizers (EM s) into phenotypic poor metabolizers (PM s) of drugs, thereby modifying their clinical response to that of genotypic PM s. Phenoconversion, usually resulting from nongenetic extrinsic factors, has a significant impact on the analysis and interpretation of genotype‐focused clinical outcome association studies and personalizing therapy in routine clinical practice. The high phenotypic variability or genotype–phenotype mismatch, frequently observed due to phenoconversion within the genotypic EM population, means that the real number of phenotypic PM subjects may be greater than predicted from their genotype alone, because many genotypic EM s would be phenotypically PM s. If the phenoconverted population with genotype–phenotype mismatch, most extensively studied forCYP2D6, is as large as the evidence suggests, there is a real risk that genotype‐focused association studies, typically correlating only the genotype with clinical outcomes, may miss clinically strong pharmacogenetic associations, thus compromising any potential for advancing the prospects of personalized medicine. This review focuses primarily on co‐medication‐induced phenoconversion and discusses potential approaches to rectify some of the current shortcomings. It advocates routine phenotyping of subjects in genotype‐focused association studies and proposes a new nomenclature to categorize study populations. Even with strong and reliable data associating patients' genotypes with clinical outcome(s), there are problems clinically in applying this knowledge into routine pharmacotherapy because of potential genotype–phenotype mismatch. Drug‐induced phenoconversion during routine clinical practice remains a major public health issue. Therefore, the principal challenges facing personalized medicine, which need to be addressed, include identification of the following factors: (i) drugs that are susceptible to phenoconversion; (ii) co‐medications that can cause phenoconversion; and (iii) dosage amendments that need to be applied during and following phenoconversion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
Clopidogrel with or without Omeprazole in Coronary Artery Disease
Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., Shook, T. L., Lapuerta, P., Goldsmith, M. A., Laine, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007964 · Cited by 1,240
POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN
Mahgoub, A., Dring, L. G., Idle, J. R., Lancaster, R., & Smith, R. L. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91430-1 · Cited by 1,183
Self-citationSachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1997) · Europe PMC (PubMed Central) · Cited by 973
(2007) · PubMed · Cited by 953
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., Kesteven, P., Christersson, C., Wahlström, B., Stafberg, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311386 · Cited by 811
The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Gaedigk, A., Simon, S., Pearce, R., Bradford, L., Kennedy, M., & Leeder, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100406 · Cited by 779
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
Kimmel, S. E., French, B., Kasner, S. E., Johnson, J. A., Anderson, J. L., Gage, B. F., Rosenberg, Y. D., Eby, C. S., Madigan, R. A., McBane, R. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310669 · Cited by 742
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjöqvist, F., & Ingelman-Sundberg, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11825 · Cited by 644
Herb-Drug Interactions: A Literature Review
Hu, Z., Yang, X., Ho, P. C. L., Chan, S. Y., Heng, P. W. S., Chan, E., Duan, W., Koh, H. L., & Zhou, S. (2005) · Drugs · doi:10.2165/00003495-200565090-00005 · Cited by 633
Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
Eichelbaum, M., Spannbrucker, N., Steincke, B., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562059 · Cited by 632
Update: Clinically Significant Cytochrome P‐450 Drug Interactions
Michalets, E. L. (1998) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03830.x · Cited by 597
The largest prospective warfarin-treated cohort supports genetic forecasting
Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., & Deloukas, P. (2009) · Blood · doi:10.1182/blood-2008-04-149070 · Cited by 550
Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F. (2010) · BMJ · doi:10.1136/bmj.c693 · Cited by 466
Discombe, G. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91898-4 · Cited by 376
Applications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 354
Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update
Wedemeyer, R.-S., & Blume, H. (2014) · Drug Safety · doi:10.1007/s40264-014-0144-0 · Cited by 310
Database analyses for the prediction of in vivo drug–drug interactions from in vitro data
Ito, K., Brown, H. S., & Houston, J. B. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02041.x · Cited by 272
Bauer, T., Bouman, H. J., van Werkum, J. W., Ford, N. F., ten Berg, J. M., & Taubert, D. (2011) · BMJ · doi:10.1136/bmj.d4588 · Cited by 266
Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population
Solus, J. F., Arietta, B. J., Harris, J. R., Sexton, D. P., Steward, J. Q., McMunn, C., Ihrie, P., Mehall, J. M., Edwards, T. L., & Dawson, E. P. (2004) · Pharmacogenomics · doi:10.1517/14622416.5.7.895 · Cited by 236
A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon
Verhoef, T. I., Ragia, G., de Boer, A., Barallon, R., Kolovou, G., Kolovou, V., Konstantinides, S., Le Cessie, S., Maltezos, E., van der Meer, F. J. M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311388 · Cited by 226
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
Bertilsson, L., Dahl, M.-L., Sjöqvist, F., Åberg-Wistedt, A., Humble, M., Johansson, I., Lundqvist, E., & Ingelman-Sundberg, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)92546-6 · Cited by 223
Kim, K., Johnson, J. A., & Derendorf, H. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004268128 · Cited by 220
Glucose Control by the Kidney: An Emerging Target in Diabetes
Marsenic, O. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.031 · Cited by 217
The pharmacogenetics of codeine hypoalgesia
Sindrup, S. H., & Br??sen, K. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00001 · Cited by 201
Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.-U., Schwab, M., & Zanger, U. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200010000-00001 · Cited by 189
Ethnic Differences in Genetic Polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1
Ozawa, S., Soyama, A., Saeki, M., Fukushima-Uesaka, H., Itoda, M., Koyano, S., Sai, K., Ohno, Y., Saito, Y., & Sawada, J.-I. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.83 · Cited by 165
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping
Frank, D., Jaehde, U., & Fuhr, U. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0250-8 · Cited by 163
Simon, T., Steg, P. G., Gilard, M., Blanchard, D., Bonello, L., Hanssen, M., Lardoux, H., Coste, P., Lefèvre, T., Drouet, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.965640 · Cited by 159
Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6.
Yu, A., Idle, J. R., Byrd, L. G., Krausz, K. W., Kupfer, A., & Gonzalez, F. J. (2003) · PubMed · doi:10.1097/01.fpc.0000054066.98065.7b · Cited by 158
The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study*
Balian, J. D., Sukhova, N., Harris, J. W., Hewett, J., Pickle, L. W., Goldstein, J. A., Woosley, R. L., & Flockhart, D. A. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90229-5 · Cited by 151
Inhibition of CYP2D6 Activity by Bupropion
Kotlyar, M., Brauer, L. H., Tracy, T. S., Hatsukami, D. K., Harris, J., Bronars, C. A., & Adson, D. E. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000162805.46453.e3 · Cited by 144
Kreutz, R. P., Stanek, E. J., Aubert, R. E., Yao, J., Breall, J. A., Desta, Z., Skaar, T. C., Teagarden, J. R., Frueh, F. W., Epstein, R. S., et al. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.8.787 · Cited by 135
Lockhart, P., & Guthrie, B. (2011) · British Journal of General Practice · doi:10.3399/bjgp11x593848 · Cited by 123
Pope, L. E., Khalil, M. H., Berg, J. E., Stiles, M. R., Yakatan, G. J., & Sellers, E. M. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004269521 · Cited by 122
Hirota, T., Eguchi, S., & Ieiri, I. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rv-085 · Cited by 115
Screening for endogenous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase.
Yu, A., Idle, J. R., Herraiz, T., Kupfer, A., & Gonzalez, F. J. (2003) · PubMed · doi:10.1097/01.fpc.0000054094.48725.b7 · Cited by 111
Herb–drug pharmacokinetic interactions reviewed
Tarirai, C., Viljoen, A. M., & Hamman, J. H. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.529129 · Cited by 106
Brockmöller, J., Kirchheiner, J., Meisel, C., & Roots, I. (2000) · Pharmacogenomics · doi:10.1517/14622416.1.2.125 · Cited by 106
Interactions between herbal and conventional medicines
Williamson, E. M. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.2.355 · Cited by 102
Genetics, Epigenetics, and Regulation of Drug-Metabolizing Cytochrome P450 Enzymes
Zanger, U. M., Klein, K., Thomas, M., Rieger, J. K., Tremmel, R., Kandel, B. A., Klein, M. B., & Magdy, T. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.220 · Cited by 99
Cronin-Fenton, D. P., Damkier, P., & Lash, T. L. (2013) · Future Oncology · doi:10.2217/fon.13.168 · Cited by 97
The African‐specific CYP2D6*17 allele encodes an enzyme with changed substrate specificity
Wennerholm, A., Dandara, C., Sayi, J., Svensson, J., Abdi, Y. A., Ingelman‐Sundberg, M., Bertilsson, L., Hasler, J. A., & Gustafsson, L. L. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.120239 · Cited by 94
Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes
Shah, R. R. (2004) · Drug Safety · doi:10.2165/00002018-200427030-00001 · Cited by 93
Self-citationHollowell, J., Meier, C. R., Haefeli, W. E., & Gasse, C. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-03-0166 · Cited by 93
Variability in drug metabolizing enzyme activity in HIV-infected patients
Jones, A. E., Brown, K. C., Werner, R. E., et al. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-009-0777-6 · Cited by 92
Caraco, Y., Sheller, J. R., & Wood, A. J. J. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34915-8 · Cited by 91
Laine, K., Tybring, G., Härtter, S., et al. (2001) · PubMed · Cited by 89
Goldstein, L. H., Elias, M. S., Avraham, G. R., Biniaurishvili, B. Z., Madjar, M., Kamargash, I., Braunstein, R., Berkovitch, M., & Golik, A. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02878.x · Cited by 85
Investigation of terbinafine as a CYP2D6 inhibitor in vivo
ABDELRAHMAN, S., Gotschall, R. R., KAUFFMAN, R., et al. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70065-2 · Cited by 84
Özdemir, V., Naranjo, C. A., Herrmann, N., Reed, K. L., Sellers, E. M., & KALOW, W. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90037-0 · Cited by 81
Tamoxifen and CYP2D6: A Contradiction of Data
Hertz, D. L., McLeod, H. L., & Irvin, W. J. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0418 · Cited by 81
Visser, L. E., Beest, F. J. A. P., Kasbergen, A. A. H., Smet, P. D., Vulto, A. G., Albert Hofman, D., & Stricker, B. H. C. (2002) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613289 · Cited by 78
Lam, Y. W. F., Gaedigk, A., Ereshefsky, L., Alfaro, C. L., & Simpson, J. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.12.1001.33603 · Cited by 78
Incidence and predictors of severe bleeding during warfarin treatment
Lindh, J. D., Holm, L., Dahl, M., et al. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0048-2 · Cited by 75
The endogenous substrates of brain CYP2D
Wang, X., Li, J., Dong, G., & Yue, J. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.12.025 · Cited by 73
Potential role of CYP2D6 in the central nervous system
Cheng, J., Zhen, Y., Miksys, S. L., Beyoğlu, D., Krausz, K. W., Tyndale, R. F., Yu, A., Idle, J. R., & Gonzalez, F. J. (2013) · Xenobiotica · doi:10.3109/00498254.2013.791410 · Cited by 73
A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer
Williams, M. L., Bhargava, P., Cherrouk, I., Marshall, J. L., Flockhart, D. A., & Wainer, I. W. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00189.x · Cited by 73
Dilger, K., Greiner, B., Fromm, M. F., Hofmann, U., Kroemer, H. K., & Eichelbaum, M. F. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00002 · Cited by 69
Hauta-Aho, M., Tirkkonen, T., Vahlberg, T., & Laine, K. (2009) · Annals of Medicine · doi:10.1080/07853890903186168 · Cited by 67
Influence of the defective metabolism of sparteine on its pharmacokinetics
Eichelbaum, M. F., Spannbrucker, N., & Dengler, H. J. (1979) · European Journal of Clinical Pharmacology · doi:10.1007/bf00562060 · Cited by 66
CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
Helsby, N. A., Lo, W.-Y., SHARPLES, K. J., Riley, G., Murray, M., Spells, K. P., Dzhelai, M., Simpson, A., & Findlay, M. P. N. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604699 · Cited by 65
Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?
Ma, T. K. W., Lam, Y., Tan, V. P. Y., & Yan, B. P. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03949.x · Cited by 63
Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles
Bogni, A., Monshouwer, M., Moscone, A., Hidestrand, M., Ingelman‐Sundberg, M., Härtung, T., & Coecke, S. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.04.001 · Cited by 61
Madani, S., Barilla, D., Cramer, J. A., Wang, Y., & Paul, C. F. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/009127002762491299 · Cited by 60
de Graan, A. M., Teunissen, S. F., Vos, F. D., Loos, W. J., van Schaik, R. H. N., de Jongh, F. E., de Vos, A. I., Alphen, R. J. V., van der Holt, B., Verweij, J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.9839 · Cited by 56
Burkard, T., Kaiser, C. A., Rocca, H. B., Osswald, S., Pfisterer, M. E., Jeger, R. V., & for the BASKET Investigators (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02423.x · Cited by 55
Differential Genotype Dependent Inhibition of CYP2C9 in Humans
Kumar, V., Brundage, R. C., Oetting, W. S., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020396 · Cited by 55
Kirchheiner, J., Bertilsson, L., Bruus, H., Wolff, A., Roots, I., & Bauer, M. (2003) · Pharmacopsychiatry · doi:10.1055/s-2003-45136 · Cited by 55
Preskorn, S., SHAH, R., NEFF, M., Golbeck, A. L., & CHOI, J. (2007) · Journal of Psychiatric Practice · doi:10.1097/00131746-200701000-00002 · Cited by 53
Self-citationSchmidt, M., Johansen, M. B., Robertson, D. J., Mæng, M., Kaltoft, A., Jensen, L. O., Tilsted, H. H., Bøtker, H. E., Sørensen, H. T., & Baron, J. A. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04890.x · Cited by 52
Brauch, H. B., & Schwab, M. G. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12229 · Cited by 49
He, S.-M., Zhou, Z.-W., Li, X., & Zhou, S.-F. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794480131 · Cited by 48
Effect of Venlafaxine versus Fluoxetine on Metabolism of Dextromethorphan, a CYP2D6 Probe
Amchin, J., Ereshefsky, L., Zarycranski, W., Taylor, K. P., Albano, D., & Klockowski, P. M. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010159 · Cited by 48
Ohnishi, A., MURAKAMI, S., Akizuki, S., Mochizuki, J., Echizen, H., & Takagi, I. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005280787 · Cited by 47
Güzey, C., Norström, Å., & Spigset, O. (2002) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200206000-00018 · Cited by 44
Role of cytochrome P450 genotype in the steps toward personalized drug therapy
Cavallari, L. H., Jeong, & Bress, A. P. (2011) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s15497 · Cited by 39
Olesen, C., Harbig, P., Barat, I., & Damsgaard, E. M. S. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3362 · Cited by 37
Cholesteryl ester transfer protein and its inhibition
Weber, O., Bischoff, H., Schmeck, C., & Böttcher, M.-F. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0418-3 · Cited by 37
CYP2D6 Genotyping and Tamoxifen: An Unfinished Story in the Quest for Personalized Medicine
de Souza, J. A., & Olopade, O. I. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.002 · Cited by 37
Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
Žourková, A., & Hadašová, E. (2003) · PubMed · Cited by 35
Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters
Haduch, A., Bromek, E., & Daniel, W. A. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71513-5 · Cited by 34
Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment.
Rost, K. L., Brockmöller, J., Esdorn, F., et al. (1995) · PubMed · Cited by 34
Zeng, Z., Liu, Y., Liu, Z., You, J., Chen, Z., Wang, J., Peng, Q., Xie, L., Li, R., Li, S., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2195-9 · Cited by 31
Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment
Rost, K. L., Brockmöller, J., Esdorn, F., & Roots, I. (1995) · Journal of Hepatology · doi:10.1016/s0168-8278(95)80005-0 · Cited by 29
Assessment of In Vivo CYP2D6 Activity: Differential Sensitivity of Commonly Used Probes to Urine pH
Özdemir, M., Crewe, K. H., Tucker, G. T., & Rostami‐Hodjegan, A. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004269582 · Cited by 27
Hospitalization for Hemorrhage Among Warfarin Recipients Prescribed Amiodarone
Lam, J., Gomes, T., Juurlink, D. N., Mamdani, M., Pullenayegum, E., Kearon, C., Spencer, F. A., Paterson, M. J., Zheng, H. Y., & Holbrook, A. M. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.03.051 · Cited by 25
Opdam, F. L., Dezentjé, V. O., den Hartigh, J., Modak, A. S., Vree, R., Batman, E., Smorenburg, C. H., Nortier, J. W. R., Gelderblom, H. A. J., & Guchelaar, H. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2034-4 · Cited by 24
High-risk antimicrobial prescriptions among ambulatory patients on warfarin
Lane, M., Devine, S. T., & McDonald, J. R. (2011) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2011.01270.x · Cited by 18
Shah, R. R. (1993) · Xenobiotica · doi:10.3109/00498259309059432 · Cited by 18
Self-citationKCNH2 pharmacogenomics summary
Oshiro, C. M., Thorn, C. F., Roden, D. M., Klein, T. E., & Altman, R. B. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283349e9c · Cited by 15
The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers
Yamada, S., Shiohira, H., Yasui‐Furukori, N., et al. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1480-1 · Cited by 12
Gschwind, L., Rollason, V., Boehlen, F., Rebsamen, M. C., Combescure, C., Grünenwald, M., Matthey, A., Bonnabry, P., Dayer, P., & Desmeules, J. A. (2013) · Pharmacogenomics · doi:10.2217/pgs.13.55 · Cited by 11
Dynamics and persistence of CYP2D6 inhibition by paroxetine
Juřica, J., & Žourková, A. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12042 · Cited by 11
6 beta‐hydroxycortisol excretion in relation to polymorphic N‐oxidation of sparteine [letter]
Park, B. K., Eichelbaum, M. F., & Ohnhaus, E. E. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01448.x · Cited by 9
Ching, G. G., Li, D., Baker, W. L., Hohl, P. K., Mather, J. F., McKay, R. G., & Lundbye, J. (2012) · PubMed · Cited by 5
Cited by
A Review of the Important Role of CYP2D6 in Pharmacogenomics
Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M. (2020) · Genes · doi:10.3390/genes11111295 · Cited by 316
Darakjian, L., Deodhar, M., Turgeon, J., & Michaud, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094967 · Cited by 53
Metadata
- Authors
- Shah, R. R., & Smith, R. L.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2015-01-20
- Volume
- 79
- Issue
- 2
- Pages
- 222-240
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2143550409
- Cited by
- 278
- References
- 98
- FWCI
- 16.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.